Overview

• The attorneys general of California, New York, Massachusetts and New Jersey filed a regulatory petition to strip mifepristone of requirements under its Risk Evaluation and Mitigation Strategy program.
• The states argue prescriber certification, patient agreement forms and pharmacy certification mandates now lack scientific justification given the pill’s 25-year safety record.
• Their filing follows a directive from Health and Human Services Secretary Robert F. Kennedy Jr. to have FDA Commissioner Marty Makary review mifepristone’s safety based on newly cited adverse event data.
• Republican lawmakers and conservative groups point to a recent study alleging higher complication rates, but reproductive health researchers have dismissed the report as methodologically flawed.
• In parallel, seventeen additional Democratic-led states and Washington, D.C., are suing the FDA in Spokane, Washington, to further loosen restrictions on the abortion pill.